Johnson & Johnson (JNJ)
Put $5,000 In These Dividend Giants and Earn Passive Income Every Quarter
Earned income has a ceiling. Passive income from dividend stocks operates differently: cash flows in whether markets are up or down, whether you're working or sleeping.
How to Play J&J Stock Post a Beat-and-Raise Performance in Q1
Johnson & Johnson's JNJ first-quarter results were better than expected as it beat estimates for both earnings and sales. Despite the blockbuster drug, Stelara's loss of exclusivity (LOE), the Innovative Medicines unit once again outperformed expectations as sales of most key drugs like Darzalex, Tremfya and Erleada beat estimates.
Coca-Cola vs. Johnson & Johnson: The Safest Dividend on Wall Street Might Surprise You
Coca-Cola (NYSE:KO | KO Price Prediction) closed 2025 with steady organic growth and a 63rd consecutive dividend increase, while Johnson & Johnson (NYSE:JNJ) opened 2026 with accelerating pharmaceutical momentum and its own 64-year dividend streak intact.
J&J Targets Double-Digit Growth by 2030 Despite Stelara Drag
J&J targets double-digit growth by 2030 despite Stelara hit, banking on Innovative Medicine strength, MedTech gains and new launches.
Johnson & Johnson (JNJ) is a Top Dividend Stock Right Now: Should You Buy?
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?
Johnson & Johnson (JNJ) Q1 2026 Earnings Call Transcript
Johnson & Johnson (JNJ) Q1 2026 Earnings Call Transcript
What Johnson & Johnson Earnings Signal for Healthcare ETFs
With Q1 earnings season well underway, it was Johnson & Johnson (JNJ) giving investors a peek at how the broader healthcare sector might perform. The healthcare giant beat expectations on Tuesday in revenue ($24.1 billion actual versus $23.6 expected) and earnings per share ($2.70 actual versus $2.66 expected).
Johnson & Johnson's Spravato sales growth signals upside for psychedelics peers like AtaiBeckley
Johnson & Johnson (NYSE:JNJ)'s Spravato is reinforcing investor interest in the broader psychedelics sector as it reported another quarter of strong sales growth, with Jefferies analysts pointing to implications for companies such as AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) and peers developing next-generation mental health treatments. Spravato (esketamine nasal spray), which is approved for treatment-resistant depression (TRD), generated $468 million in global sales in the first quarter of 2026, representing a 46% increase year over year.
Johnson & Johnson Q2 Earnings Review: Why You Should Be Buying The Stock Today
Johnson & Johnson delivered a robust Q1, with revenues up nearly 10% YoY to $24.1bn and a raised full-year 2026 sales guidance above $100bn. JNJ's diversified portfolio—driven by double-digit growth in Innovative Medicines and strong growth in MedTech—positions it as "the cleanest growth story in healthcare." Most key products face minimal near-term patent risk, while new launches like icotrokinra, Rybrevant, and Inlexzo offer multibillion-dollar potential.
J&J Beats Q1 Earnings & Sales Estimates, Raises 2026 Outlook
JNJ tops Q1 earnings and sales estimates, lifts 2026 outlook as strong oncology and MedTech growth offset steep Stelara decline.
Johnson and Johnson Raises Dividend for 64th Consecutive Year
Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) declared its 64th consecutive annual dividend increase on April 14, 2026, lifting its quarterly payout from $1.30 per share to $1.34 per share, a 3% increase.
Johnson & Johnson (JNJ) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for Johnson & Johnson (JNJ) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
